MDxHealth « Terug naar discussie overzicht

quote:

inspirator schreef op 4 mei 2015 22:33:

MDXH should be worth at least 15.25 Euros a share compared to the current share price of 5 Euros a share and maybe much more over time. Biotech and smaller healthcare companies in Europe are often cheaper than their US equivalents.

seekingalpha.com/article/3118556-mdxh...

Morgen spin-off na publicatie Q1 cijfers MDxHealth en wederom publiciteit voor MDxHealth

quote:

inspirator schreef op 1 november 2015 18:41:

[...]

We are pleased to announce our recent acquisition of NovioGendix. MDxHealth will continue the ongoing research, development and commercialization of novel molecular assays for urologic oncology, including SelectMDx for Prostate Cancer test (formerly named Quattro).

The first product that MDxHealth will launch in the European market is SelectMDx for Prostate Cancer. This urine-based test is the successor of the PCA3 test that was identified and developed by professor Dr. Jack A. Schalken and his team at the Radboudumc. In the past years, professor Dr. Schalken and the NovioGendix team developed this next generation non-invasive, ‘liquid biopsy’ test, to more accurately distinguish patients who may harbor clinically significant prostate cancer compared to the PCA3 test. SelectMDx™ can aid in the discrimination between patients with an increased likelihood for high-grade prostate cancer from those with low-grade disease, for whom a prostate biopsy may enable earlier detection.

In November 2014, NovioGendix transferred its routine PCA3 testing services to DDL Diagnostic Laboratory in Rijswijk. However, DDL will no longer provide PCA3 testing services after the 1st of December 2015. Starting on November 1st, 2015, the SelectMDx™ test is available at MDxHealth in Nijmegen.

quote:

inspirator schreef op 3 november 2015 07:25:

Indien koers net zo hard stijgt als omzet, komt koers van 15 euro per aandeel MdxHealth in zicht:

Revenue for the first nine months up 44% to $11.9 million
67% increase in case volume from previous quarter and 30% year-on-year growth
Expansion of uro-oncology product offering and global commercial strategy
- See more at: globenewswire.com/news-release/2015/1...

quote:

inspirator schreef op 3 november 2015 09:12:

[...]

MdxHealth nog ondergewaardering van 11 euro per aandeel.

op lange termijn 32 euro per aandeel

quote:

inspirator schreef op 3 november 2015 09:23:

[...]

Nog effe tegenwerking van gsa capital.

Zojuist ook een ander puistje uitgeknepen.

quote:

inspirator schreef op 3 november 2015 20:28:

Op naar 47 euro per aandeel MdxHealth middels global commercial strategy:

"With the acquisition of NovioGendix and continued development of our existing pipeline this past quarter, we have established a solid foundation for our expanded uro-oncology product offering and the progression of our global commercial strategy. On November 1st, we launched SelectMDx(TM) for Prostate Cancer service testing in the Benelux region and look forward to launching our CE marked SelectMDx kits across Europe and in the U.S. in the beginning of 2016. Additionally, with promising data to date, and ongoing validation studies for our urine-based bladder cancer test, we continue to expand our novel liquid biopsy product pipeline, which we expect to be a key focus of our future commercial portfolio."

quote:

inspirator schreef op 4 november 2015 19:54:

[...]

We wisten al dat MdxHealth de wereld gaat veroveren met cancer diagnosicts products.

Het is ethisch onverantwoord dat een shortpartij een aanslag pleegde op een oncologisch bedrijf zoals MdxHealth.

Maar nu er waardering komt voor producten van MdxHealth wereldwijd, is koersexplosie aanstaande.

Nog effe en koers MdxHealth beweegt zich ergens tussen 15 en 47 euro.

quote:

Rolootje schreef op 5 november 2015 22:21:

Vandaag mijn positie verdubbeld, ze gaan voor de lange termijn op de plank onder de 4 euro (liever niet:)) verdubbel ik nog een keer Succes allen!